Search

Your search keyword '"Devine, Dana V."' showing total 611 results
Start Over Author "Devine, Dana V."
611 results on '"Devine, Dana V."'

2. Clinical Practice Guidelines From the Association for the Advancement of Blood and Biotherapies (AABB): COVID-19 Convalescent Plasma

Author

Estcourt, Lise J, Cohn, Claudia S, Pagano, Monica B, Iannizzi, Claire, Kreuzberger, Nina, Skoetz, Nicole, Allen, Elizabeth S, Bloch, Evan M, Beaudoin, Gregory, Casadevall, Arturo, Devine, Dana V, Foroutan, Farid, Gniadek, Thomas J, Goel, Ruchika, Gorlin, Jed, Grossman, Brenda J, Joyner, Michael J, Metcalf, Ryan A, Raval, Jay S, Rice, Todd W, Shaz, Beth H, Vassallo, Ralph R, Winters, Jeffrey L, and Tobian, Aaron AR

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Prevention, Clinical Trials and Supportive Activities, Clinical Research, Rare Diseases, Cancer, Good Health and Well Being, COVID-19, Hospitalization, Humans, Immunization, Passive, SARS-CoV-2, COVID-19 Serotherapy, Medical and Health Sciences, General & Internal Medicine, Clinical sciences
Abstract

DescriptionCoronavirus disease 2019 convalescent plasma (CCP) has emerged as a potential treatment of COVID-19. However, meta-analysis data and recommendations are limited. The Association for the Advancement of Blood and Biotherapies (AABB) developed clinical practice guidelines for the appropriate use of CCP.MethodsThese guidelines are based on 2 living systematic reviews of randomized controlled trials (RCTs) evaluating CCP from 1 January 2019 to 26 January 2022. There were 33 RCTs assessing 21 916 participants. The results were summarized using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) method. An expert panel reviewed the data using the GRADE framework to formulate recommendations.Recommendation 1 (outpatient)The AABB suggests CCP transfusion in addition to the usual standard of care for outpatients with COVID-19 who are at high risk for disease progression (weak recommendation, moderate-certainty evidence).Recommendation 2 (inpatient)The AABB recommends against CCP transfusion for unselected hospitalized persons with moderate or severe disease (strong recommendation, high-certainty evidence). This recommendation does not apply to immunosuppressed patients or those who lack antibodies against SARS-CoV-2.Recommendation 3 (inpatient)The AABB suggests CCP transfusion in addition to the usual standard of care for hospitalized patients with COVID-19 who do not have SARS-CoV-2 antibodies detected at admission (weak recommendation, low-certainty evidence).Recommendation 4 (inpatient)The AABB suggests CCP transfusion in addition to the usual standard of care for hospitalized patients with COVID-19 and preexisting immunosuppression (weak recommendation, low-certainty evidence).Recommendation 5 (prophylaxis)The AABB suggests against prophylactic CCP transfusion for uninfected persons with close contact exposure to a person with COVID-19 (weak recommendation, low-certainty evidence).Good clinical practice statementCCP is most effective when transfused with high neutralizing titers to infected patients early after symptom onset.

Published
2022

7. Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial

Author

Bégin, Philippe, Callum, Jeannie, Jamula, Erin, Cook, Richard, Heddle, Nancy M., Tinmouth, Alan, Zeller, Michelle P., Beaudoin-Bussières, Guillaume, Amorim, Luiz, Bazin, Renée, Loftsgard, Kent Cadogan, Carl, Richard, Chassé, Michaël, Cushing, Melissa M., Daneman, Nick, Devine, Dana V., Dumaresq, Jeannot, Fergusson, Dean A., Gabe, Caroline, Glesby, Marshall J., Li, Na, Liu, Yang, McGeer, Allison, Robitaille, Nancy, Sachais, Bruce S., Scales, Damon C., Schwartz, Lisa, Shehata, Nadine, Turgeon, Alexis F., Wood, Heidi, Zarychanski, Ryan, Finzi, Andrés, and Arnold, Donald M.

Published
2021
Full Text
View/download PDF

8. Characterization and Hemocompatibility of α, β, and γ Cyclodextrin-Modified Magnetic Nano-Adsorbents.

Author

Ghaffari Sharaf, Mehdi, Li, Shuhui, Rowe, Elyn M., Devine, Dana V., and Unsworth, Larry D.

Subjects
SMALL molecules, CHRONIC kidney failure, BLOOD platelet activation, PROTEIN structure, NANOPARTICLES
Abstract

Kidney dysfunction leads to the retention of metabolites within the blood that are not effectively cleared with conventional hemodialysis. Magnetic nanoparticle (MNP)-based absorbents have inherent properties that make them amenable to capturing toxins in the blood, notably a large surface area that can be chemically modified to enhance toxin capture and the ability to be easily collected from the blood using an external magnetic field. Cyclodextrins (CDs) present a chemical structure that facilitates the binding of small molecules. However, the hemocompatibility of MNPs modified with films composed of different native types of CDs (α, β, or γ) has not yet been investigated, which is information crucial to the potential clinical application of MNPs to supplement hemodialysis. To this end, films of α-, β-, or γ-CDs were formed on MNPs and characterized. The impact of these films on the adsorbed protein structure, composition of key adsorbed proteins, and clotting kinetics were evaluated. It was found that modified MNPs did not significantly affect the secondary structure of some proteins (albumin, lysozyme, α-lactalbumin). The adsorbed proteome from platelet-poor human plasma was evaluated as a function of film properties. Compared to non-modified nanoparticles, CD-modified MNPs exhibited a significant decrease in the adsorbed protein per surface area of MNPs. The immunoblot results showed variations in the adsorption levels of C3, fibrinogen, antithrombin, Factor XI, and plasminogen across CD-modified MNPs. The hemocompatibility experiments showed that CD-modified MNPs are compatible with human whole blood, with no significant impact on platelet activation, hemolysis, or hemostasis. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

11. Convalescent plasma for adults with acute COVID-19 respiratory illness (CONCOR-1): study protocol for an international, multicentre, randomized, open-label trial

Author

Bégin, Philippe, Callum, Jeannie, Heddle, Nancy M., Cook, Richard, Zeller, Michelle P., Tinmouth, Alan, Fergusson, Dean A., Cushing, Melissa M., Glesby, Marshall J., Chassé, Michaël, Devine, Dana V., Robitalle, Nancy, Bazin, Renée, Shehata, Nadine, Finzi, Andrés, McGeer, Allison, Scales, Damon C., Schwartz, Lisa, Turgeon, Alexis F., Zarychanski, Ryan, Daneman, Nick, Carl, Richard, Amorim, Luiz, Gabe, Caroline, Ellis, Martin, Sachais, Bruce S., Loftsgard, Kent Cadogan, Jamula, Erin, Carruthers, Julie, Duncan, Joanne, Lucier, Kayla, Li, Na, Liu, Yang, Armali, Chantal, Kron, Amie, Modi, Dimpy, Auclair, Marie-Christine, Cerro, Sabrina, Avram, Meda, and Arnold, Donald M.

Published
2021
Full Text
View/download PDF

12. Measurement of lead, mercury, and cadmium in blood donors in Canada.

Author

Hadjesfandiari, Narges, Serrano, Katherine, Richardson‐Sanchez, Tomas, Barakauskas, Vilte E., Yi, Qi‐Long, Murphy, Michael, and Devine, Dana V.

Subjects
LEAD, INDUCTIVELY coupled plasma mass spectrometry, BLOOD donors, CADMIUM, MERCURY
Abstract

Background: Fetal and neonatal exposure to lead is associated with irreversible adverse effects on neural development. There is no reliable threshold for lead effect, so limiting exposure is recommended. A significant correlation has been reported between post‐transfusion blood lead level (BLL) in infants and lead levels in transfused RBC units. We measured levels of lead, mercury, and cadmium, in Canadian donor blood to investigate if concerning levels for neonatal transfusion exist. Study Design and Methods: Whole blood samples from blood donors (n = 2529) were shipped cold within 7 days of donation. All permanent blood donation clinics across Canada were sampled. Twelve of these permanent clinics and 8 mobile clinics with a greater potential for having higher lead or mercury levels were oversampled. Heavy metals were measured by inductively coupled plasma mass spectrometry. Results: Of all donations, 2.2% (lead) and 0.4% (mercury) had levels higher than the recommended thresholds for safe neonatal transfusion. BLLs were higher in males but there was no significant difference in the blood mercury levels of males versus females. Cadmium levels were higher in females. There was a positive correlation between donor age and levels of heavy metals, with lead having the strongest correlation (r = 0.47, p <.0001). Three clinics in close proximity to two lead‐producing mines were among the clinics with the highest BLLs. Significantly higher blood mercury levels were observed in coastal clinics. Conclusion: Our data on donor blood heavy metal levels supports considering blood transfusion as an exposure source to heavy metals and encourages informed selection of blood units for transfusion to vulnerable groups. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

13. Plaquettes conservées au froid pour les saignements aigus chez les patient·es de chirurgie cardiaque : un compte rendu narratif

Author

Lu, Justin, primary, Karkouti, Keyvan, additional, Peer, Miki, additional, Englesakis, Marina, additional, Spinella, Philip C., additional, Apelseth, Torunn O., additional, Scorer, Thomas G., additional, Kahr, Walter H. A., additional, McVey, Mark, additional, Rao, Vivek, additional, Abrahamyan, Lusine, additional, Lieberman, Lani, additional, Mewhort, Holly, additional, Devine, Dana V., additional, Callum, Jeannie, additional, and Bartoszko, Justyna, additional

Published
2023
Full Text
View/download PDF

14. Barriers and enablers to source plasma donation by gay, bisexual and other men who have sex with men under revised eligibility criteria: protocol for a multiple stakeholder feasibility study

Author

Vesnaver, Elisabeth, Goldman, Mindy, O’Brien, Sheila, MacPherson, Paul, Butler-Foster, Terrie, Lapierre, Don, Otis, Joanne, Devine, Dana V., Germain, Marc, Rosser, Andrew, MacDonagh, Richard, Randall, Taylor, Osbourne-Sorrell, William, Clement-Thorne, Broderic, Al-Bakri, Taim Bilal, Rubini, Kyle A., Hill, Nolan E., and Presseau, Justin

Published
2020
Full Text
View/download PDF

15. Author Correction: Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial

Author

Bégin, Philippe, Callum, Jeannie, Jamula, Erin, Cook, Richard, Heddle, Nancy M., Tinmouth, Alan, Zeller, Michelle P., Beaudoin-Bussières, Guillaume, Amorim, Luiz, Bazin, Renée, Loftsgard, Kent Cadogan, Carl, Richard, Chassé, Michaël, Cushing, Melissa M., Daneman, Nick, Devine, Dana V., Dumaresq, Jeannot, Fergusson, Dean A., Gabe, Caroline, Glesby, Marshall J., Li, Na, Liu, Yang, McGeer, Allison, Robitaille, Nancy, Sachais, Bruce S., Scales, Damon C., Schwartz, Lisa, Shehata, Nadine, Turgeon, Alexis F., Wood, Heidi, Zarychanski, Ryan, Finzi, Andrés, and Arnold, Donald M.

Published
2022
Full Text
View/download PDF

19. International Society of Blood Transfusion survey of experiences of blood banks and transfusion services during the <scp>COVID</scp> ‐19 pandemic

Author

Al-Riyami, Arwa Z., Burnouf, Thierry, Wood, Erica M., Devine, Dana V., Oreh, Adaeze, Apelseth, Torunn Oveland, Goel, Ruchika, Bloch, Evan M., van Den Berg, Karin, Getshen, Mahrukh, Louw, Vernon, Ang, Ai Leen, Lee, Cheuk Kwong, Rahimi-Levene, Naomi, Stramer, Susan L., Vassallo, Ralph, Schulze, Torsten J., Patidar, Gopal Kumar, Pandey, Hem Chandra, Dubey, Rounak, Badawi, Maha, Hindawi, Salwa, Meshi, Abdullah, Matsushita, Tadashi, Sorrentino, Enrico, Grubovic Rastvorceva, Rada M., Bazin, Renée, Vermeulen, Marion, Nahirniak, Susan, Tsang, Hamilton C., Vrielink, Hans, Triyono, Teguh, Addas-Carvalho, Marcelo, Hećimović, Ana, Torres, Oscar W., Mutindu, Samclide M., Bengtsson, Jesper, Dominguez, Diego, Sayedahmed, Ahmed, Hanisa Musa, Rozi, Gautam, Bipul, Herczenik, Eszter, So-Osman, Cynthia, and Hematology

Subjects
SDG 3 - Good Health and Well-being, Surveys and Questionnaires, Clinical medicine, Immunization, Passive, Blood Banks, COVID-19, Humans, Blood Donors, Blood Transfusion, Hematology, General Medicine, Pandemics, COVID-19 Serotherapy
Abstract

Background and Objectives: The coronavirus disease 2019 (COVID-19) pandemic has impacted blood systems worldwide. Challenges included maintaining blood supplies and initiating the collection and use of COVID-19 convalescent plasma (CCP). Sharing information on the challenges can help improve blood collection and utilization. Materials and Methods: A survey questionnaire was distributed to International Society of Blood Transfusion members in 95 countries. We recorded respondents' demographic information, impacts on the blood supply, CCP collection and use, transfusion demands and operational challenges. Results: Eighty-two responses from 42 countries, including 24 low- and middle-income countries, were analysed. Participants worked in national (26.8%) and regional (26.8%) blood establishments and hospital-based (42.7%) institutions. CCP collection and transfusion were reported by 63% and 36.6% of respondents, respectively. Decreases in blood donations occurred in 70.6% of collecting facilities. Despite safety measures and recruitment strategies, donor fear and refusal of institutions to host blood drives were major contributing factors. Almost half of respondents working at transfusion medicine services were from large hospitals with over 10,000 red cell transfusions per year, and 76.8% of those hospitals experienced blood shortages. Practices varied in accepting donors for blood or CCP donations after a history of COVID-19 infection, CCP transfusion, or vaccination. Operational challenges included loss of staff, increased workloads and delays in reagent supplies. Almost half of the institutions modified their disaster plans during the pandemic. Conclusion: The challenges faced by blood systems during the COVID-19 pandemic highlight the need for guidance, harmonization, and strengthening of the preparedness and the capacity of blood systems against future infectious threats.

Published
2022
Full Text
View/download PDF

25. A data‐informed system to manage scarce blood product allocation in a randomized controlled trial of convalescent plasma

Author

Li, Na, primary, Zeller, Michelle P., additional, Shih, Andrew W., additional, Heddle, Nancy M., additional, St. John, Melanie, additional, Bégin, Philippe, additional, Callum, Jeannie, additional, Arnold, Donald M., additional, Akbari‐Moghaddam, Maryam, additional, Down, Douglas G., additional, Jamula, Erin, additional, Devine, Dana V., additional, and Tinmouth, Alan, additional

Published
2022
Full Text
View/download PDF

35. Early and out-of-hospital use of COVID-19 convalescent plasma:An international assessment of utilization and feasibility

Author

Al-Riyami, Arwa Z., Estcourt, Lise, Rahimi-Levene, Naomi, Bloch, Evan M., Goel, Ruchika, Tiberghien, Pierre, Thibert, Jean Baptiste, Bruun, Mie Topholm, Devine, Dana V., Gammon, Richard R., Wendel, Silvano, Toungouz Nevessignsky, Michel, Grubovic Rastvorceva, Rada M., Oreh, Adaeze, Romon, Iñigo, van den Berg, Karin, Kitazawa, Junichi, Patidar, Gopal, So-Osman, Cynthia, Wood, Erica M., Al-Riyami, Arwa Z., Estcourt, Lise, Rahimi-Levene, Naomi, Bloch, Evan M., Goel, Ruchika, Tiberghien, Pierre, Thibert, Jean Baptiste, Bruun, Mie Topholm, Devine, Dana V., Gammon, Richard R., Wendel, Silvano, Toungouz Nevessignsky, Michel, Grubovic Rastvorceva, Rada M., Oreh, Adaeze, Romon, Iñigo, van den Berg, Karin, Kitazawa, Junichi, Patidar, Gopal, So-Osman, Cynthia, and Wood, Erica M.

Abstract

Background and Objectives The use of coronavirus disease 2019 (COVID-19) convalescent plasma (CCP) in the treatment of patients with severe acute respiratory syndrome-2 infection has been controversial. Early administration of CCP before hospital admission offers a potential advantage. This manuscript summarizes current trials of early use of CCP and explores the feasibility of this approach in different countries. Materials and Methods A questionnaire was distributed to the International Society of Blood Transfusion (ISBT) CCP working group. We recorded respondents' input on existing trials on early/outpatient CCP and out-of-hospital (OOH)/home transfusion (HT) practices in their countries and feedback on challenges in initiating home CCP infusion programmes. In addition, details of existing trials registered on clinicaltrials.gov were summarized. Results A total of 31 country representatives participated. Early/OOH CCP transfusion studies were reported in the United States, the Netherlands, Spain and Brazil. There were a total of six published and five ongoing trials on the prophylactic and therapeutic early use of CCP. HT was practised in Australia, the UK, Belgium, France, Japan, Nigeria, the Netherlands, Spain, Italy, Norway, the United States and some provinces in Canada. Thirty-four representatives indicated a lack of OOH CCP or HT in their institutions and countries. Barriers to implementation of OOH/HT included existing legislation, lack of policies pertaining to outpatient transfusion, and associated logistical challenges, including lack of staffing and resources. Conclusion Early administration of CCP remains a potential option in COVID-19 management in countries with existing OOH/HT programmes. Legislation and regulatory bodies should consider OOH/HT practice for transfusion in future pandemics.

Published
2022

37. Author Correction: Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial (Nature Medicine, (2021), 27, 11, (2012-2024), 10.1038/s41591-021-01488-2)

Author

Bégin, Philippe, Callum, Jeannie, Jamula, Erin, Cook, Richard, Heddle, Nancy M., Tinmouth, Alan, Zeller, Michelle P., Beaudoin-Bussières, Guillaume, Amorim, Luiz, Bazin, Renée, Loftsgard, Kent Cadogan, Carl, Richard, Chassé, Michaël, Cushing, Melissa M., Daneman, Nick, Devine, Dana V., Dumaresq, Jeannot, Fergusson, Dean A., Gabe, Caroline, Glesby, Marshall J., Li, Na, Liu, Yang, McGeer, Allison, Robitaille, Nancy, Sachais, Bruce S., Scales, Damon C., Schwartz, Lisa, Shehata, Nadine, Turgeon, Alexis F., and Wood, Heidi

Abstract

In the version of this Article initially published, there was an omission in the member list for the CONCOR-1 Study Group. Valérie Arsenault (Héma-Québec, Montreal, Quebec, Canada) has now been included in the CONCOR-1 Study Group in the online version of the article.

Published
2022

38. Reply to: Concerns about estimating relative risk of death associated with convalescent plasma for COVID-19

Author

Bégin, Philippe, Callum, Jeannie, Cook, Richard, Jamula, Erin, Liu, Yang, Finzi, Andrés, Heddle, Nancy M., Tinmouth, Alan, Zeller, Michelle P., Beaudoin-Bussières, Guillaume, Amorim, Luiz, Bazin, Renée, Loftsgard, Kent Cadogan, Carl, Richard, Chassé, Michaël, Cushing, Melissa M., Daneman, Nick, Devine, Dana V., Dumaresq, Jeannot, Fergusson, Dean A., Gabe, Caroline, Glesby, Marshall J., Li, Na, McGeer, Allison, Robitaille, Nancy, Sachais, Bruce S., Scales, Damon C., Schwartz, Lisa, Shehata, Nadine, and Turgeon, Alexis F.

Subjects
General Medicine, General Biochemistry, Genetics and Molecular Biology
Published
2022

44. Retention of hemostatic and immunological properties of frozen plasma and COVID ‐19 convalescent apheresis fresh‐frozen plasma produced and freeze‐dried in Canada

Author

Sheffield, William P., primary, Bhakta, Varsha, additional, Howell, Anita, additional, Jenkins, Craig, additional, Serrano, Katherine, additional, Johnson, Nathaniel, additional, Lin, Yi‐Chan J., additional, Colwill, Karen, additional, Rathod, Bhavisha, additional, Greenberg, Brianna, additional, Gingras, Anne‐Claude, additional, Evans, David H., additional, Flaumenhaft, Elissa, additional, Beckett, Andrew, additional, Drews, Steven J., additional, and Devine, Dana V., additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results